Summit Therapeutics PLC (ADR) (SMMT) was Initiated by H.C. Wainwright to “Buy” and the brokerage firm has set the Price Target at $26. H.C. Wainwright advised their investors in a research report released on Sep 16, 2016.
Summit Therapeutics PLC (ADR) closed down -0.0101 points or -0.16% at $6.2499 with 3,050 shares getting traded on Wednesday. Post opening the session at $6.0101, the shares hit an intraday low of $6.0101 and an intraday high of $6.25 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
Summit Therapeutics plc formerly Summit Corporation plc is a United Kingdom-based biopharmaceutical company. The Company is focused on the discovery development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. The Company is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The Company’s lead DMD product candidate is SMT C1100 an orally administered small molecule. The Company’s lead CDI product candidate is SMT19969 an orally administered small molecule antibiotic. The Company subsidiaries include Summit Therapeutics Inc. Summit (Oxford) Limited Summit (Wales) Limited and MuOx Limited among others.